LivaNova PLC (NASDAQ:LIVN) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. lessened its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 50.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,036,248 shares of the company's stock after selling 1,055,762 shares during the quarter. Point72 Asset Management L.P. owned approximately 1.91% of LivaNova worth $47,989,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new position in LivaNova in the 4th quarter valued at about $715,000. ProShare Advisors LLC grew its holdings in shares of LivaNova by 41.2% in the fourth quarter. ProShare Advisors LLC now owns 17,902 shares of the company's stock valued at $829,000 after purchasing an additional 5,228 shares in the last quarter. Parkman Healthcare Partners LLC grew its holdings in shares of LivaNova by 72.0% in the fourth quarter. Parkman Healthcare Partners LLC now owns 174,934 shares of the company's stock valued at $8,101,000 after purchasing an additional 73,205 shares in the last quarter. Man Group plc increased its stake in LivaNova by 5.1% during the 4th quarter. Man Group plc now owns 547,781 shares of the company's stock worth $25,368,000 after buying an additional 26,558 shares during the period. Finally, Nomura Holdings Inc. acquired a new stake in LivaNova during the 4th quarter worth approximately $333,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Down 2.9%

LIVN stock traded down $1.28 during trading on Wednesday, hitting $43.60. 138,440 shares of the company's stock were exchanged, compared to its average volume of 645,553. The business has a 50-day moving average price of $38.61 and a two-hundred day moving average price of $44.76. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of 104.23 and a beta of 0.84. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $61.94.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Barclays dropped their price target on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research note on Thursday, May 8th. Stifel Nicolaus lowered their target price on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a research note on Tuesday. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.